The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience
Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score >= B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2017 |
Verlag/Hrsg.: |
WILEY
|
Schlagwörter: | direct-acting antiviral therapy / hepatitis C / hepatocellular carcinoma / pegylated interferon |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26529379 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/1942/25779 |